McLellan lab secures NIH funding

Glaucoma is a leading cause of irreversible blindness that results from loss of neurons and glial scarring of the optic nerve. Our goal in this project is to limit damage to the optic nerve by repurposing an existing “multi- functional” drug to complement existing glaucoma treatments. By delineating its effects on the optic nerve head, within a clinically relevant treatment window in an appropriate model, our studies will accelerate translation of this promising new combinatorial strategy to preserve vision in patients diagnosed with glaucoma.

The $1,875,000 research grant from National Eye Institute will fund studies to determine the effectiveness of a new glaucoma treatment strategy, while enhancing understanding of mechanisms responsible for optic nerve scarring in glaucoma